ASTM F2901 Standard Guide for Selection of Tests to Evaluate Potential Neurotoxicity of Medical Devices

The standard “ASTM F2901 Standard guide for selection of tests to evaluate potential neurotoxicity of medical devices” developed by the American Society for Testing and Materials (ASTM) describes basic information and recommendations on neurotoxicity testing methods.

Medical devices can cause adverse effects on the structure or function of the nervous system. This standard defines these adverse effects as neurotoxicity. This standard should be used in conjunction with ASTM F748 Standard Practice for Selecting Biological Test Methods for Materials and Devices and may be useful when neurotoxicity testing is necessary to evaluate medical devices that come into contact with central or peripheral nervous system tissue or cerebrospinal fluid. However, the results of these in vitro and in vivo tests may not necessarily reflect actual human responses.

The purpose of this standard is to propose a biological test panel that can be used in addition to the tests recommended in ASTM F748. This standard is designed to detect neurotoxicity caused by medical devices that come into contact with nervous tissue.

Testing recommendations should be considered for new materials, established materials with different manufacturing methods that may affect nerve tissue response, or materials used in new nerve tissue applications.

Chemical characterization can be used to assess the similarity of materials with a history of clinical use in similar neural tissue applications.

Tests should be performed on the terminally sterilized device, representative samples from the terminally sterilized device, or materials processed in the same manner as the terminally sterilized device. Representative samples should include all component materials that undergo the same manufacturing, cleaning, and sterilization processes as the terminally sterilized device and have direct or indirect tissue contact to an appropriate extent.

Testing individual materials can be useful for research and development, but a definitive neurotoxicity assessment must cover all materials in the final version of the device. The tested product must undergo all stages of production, including processing, cleaning, sterilization, and packaging.

A complete description of all device materials and reagents used during manufacturing and processing should be provided, along with information on their source, purity, and toxicity profile. Chemical characterization studies can provide additional information about the device safety profile. Information on chemical characterization of materials is available in ISO 10993-18.

To assess the neurotoxicity of medical devices within the scope of this standard, the following tests should be considered:

• Cytotoxicity tests: These are sensitive screening tools that often serve as the starting point for assessing medical device biocompatibility.
• Genotoxicity: Nerve tissue contains proliferating cell populations and may respond proliferatively to device implantation. Nerve tissue is also known to give rise to various types of tumors. A genotoxicity testing panel is recommended to ensure that medical devices do not contain genotoxic chemicals.
• Implantation: The use of a clinically relevant implantation study is recommended. The implantation site and animal model should be selected and justified based on the intended clinical use of the medical device.
• Pyrogen testing: Pyrogen testing is recommended on terminally sterilized medical devices to reduce the possibility of a neuroinflammatory response to the device. Material-mediated pyrogen testing should be performed using the rabbit pyrogen test.

The ASTM F2901 standard is a critical resource in the field of medical device safety. This standard provides recommendations for evaluating the potential neurotoxic effects of medical devices that come into contact with nervous system tissues or cerebrospinal fluid. As medical devices increasingly interact with the nervous system, ensuring their safety is crucial to prevent adverse effects such as astrocytosis, microglial activation, myelinopathy, or neurodegeneration.

ASTM F2901 is designed to complement the test protocols described in ASTM F748, which provides general guidelines for biocompatibility testing of medical devices. ASTM F2901 specifically focuses on neurotoxicity, defined as the adverse effects caused by medical devices on the structure or function of the nervous system. It is applicable to devices that contact central or peripheral nervous system tissues or cerebrospinal fluid and provides a framework for evaluating both new materials and established materials used in new applications or different manufacturing methods that may affect nervous tissue response.

The test methods recommended in ASTM F2901 generally fall into two categories: in vitro (cell-based, laboratory-controlled) and in vivo (animal-based) tests. These tests are designed to detect changes in nervous system structure or function caused by the device or its materials. While this standard does not list specific protocols, it does provide guidance on selecting tests appropriate to the device's risk profile. Common test methods include:

• In vitro test methods:
  • Cell viability tests: These tests evaluate whether materials or substances leaking from the device are toxic to nerve cells (for example, neurons, astrocytes, or microglia). Examples include MTT assays, LDH release assays, or live/dead staining to measure cell viability and proliferation.
  • Cytotoxicity testing: Evaluates the toxic effects of device materials on cultured nerve cells, usually using standardized protocols such as the ISO 10993-5 standard.
  • Functional assays: Measure changes in nerve cell function, such as neurotransmitter release, ion channel activity, or synaptic activity, which may indicate neurotoxic effects.
  • Markers of oxidative stress and inflammation: Tests used to detect the production of reactive oxygen species or inflammatory cytokines in nerve cells exposed to device materials indicate potential neurotoxicity.
• In vivo test methods:
  • Implantation studies: Involve the implantation of the device or its materials in animal models (e.g., rodents or larger mammals) to evaluate local and systemic effects on nervous tissue. These studies evaluate histopathological changes, such as neuronal loss, gliosis, or demyelination, in tissues such as the brain, spinal cord, or peripheral nerves.
  • Behavioral assessments: Animal behavior is monitored to detect functional changes in the nervous system (motor deficits, sensory impairments, or cognitive changes that may indicate neurotoxicity).
  • Neuroimaging or electrophysiology: Techniques such as MRI, CT, and similar are used to assess structural or functional changes in the nervous system after exposure to the device.
  • Cerebrospinal fluid analysis: Tests for devices that come into contact with cerebrospinal fluid may include analyzing samples for markers of inflammation, protein changes, or cellular damage.

The primary goal of ASTM F2901 is to improve the safety assessment of medical devices that interact with the nervous system. This standard proposes a standardized test panel that systematically assesses potential neurotoxic effects. This is particularly important for devices such as neural implants, spinal devices, or catheters that come into contact with cerebrospinal fluid, where neurotoxicity can have serious clinical consequences.

This standard is designed for use by manufacturers, researchers, and regulatory agencies to ensure that medical devices meet rigorous safety standards. It also supports innovation by providing a framework for evaluating new materials or manufacturing techniques and ensuring they do not pose unnecessary risks to patients.

ASTM F2901 recognizes that the proposed test results may not directly correlate with human responses due to biological variability and the complexity of nervous system interactions. Furthermore, the standard does not cover all possible safety concerns, and users should integrate it with other relevant standards and regulatory requirements to ensure comprehensive safety assessments.

As a result, ASTM F2901 is a vital tool in the development and evaluation of medical devices that interact with the nervous system. By providing a structured approach to neurotoxicity testing, it helps ensure these devices are safe for clinical use. As medical technology advances, ASTM F2901 and similar standards play a crucial role in balancing innovation with patient safety, providing clear guidance to both manufacturers and regulators.

Our organization, which has been operating for many years and meticulously follows global developments in science and technology, conducts testing, measurement, and analysis in a wide range of areas for businesses across all sectors with a skilled team and extensive infrastructure. In this context, we also provide testing services in accordance with ASTM F2901, Standard Guide for Selection of Tests to Assess the Potential Neurotoxicity of Medical Devices.